Arbutus Biopharma Corp (ABUS) SEC filings

ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3082% below fair value

$3.88+0.06 (+1.57%)

Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –

SEC filings

40 of Arbutus Biopharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	8-K	Nov 12, 2026	Nov 12, 2026	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Oct 20, 2026	Oct 22, 2026	SEC EDGAR
Current report	8-K	Aug 21, 2026	Aug 21, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Aug 12, 2026	Aug 12, 2026	SEC EDGAR
Current report	8-K	Jul 15, 2026	Jul 16, 2026	SEC EDGAR
Current report	8-K	May 26, 2026	May 27, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	May 13, 2026	May 13, 2026	SEC EDGAR
Current report	8-K	Apr 14, 2026	Apr 15, 2026	SEC EDGAR
Proxy statement	DEF 14A	May 26, 2026	Apr 14, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 23, 2026	Mar 23, 2026	SEC EDGAR
Current report	8-K	Mar 3, 2026	Mar 3, 2026	SEC EDGAR
Current report	8-K	Feb 17, 2026	Feb 20, 2026	SEC EDGAR
Current report	8-K	Feb 2, 2026	Feb 6, 2026	SEC EDGAR
Current report	8-K	Jan 15, 2026	Jan 16, 2026	SEC EDGAR
Current report	8-K	Dec 11, 2025	Dec 11, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	8-K	Oct 7, 2025	Oct 7, 2025	SEC EDGAR
Current report	8-K	Sep 9, 2025	Sep 10, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Aug 4, 2025	Aug 6, 2025	SEC EDGAR
Current report	8-K	Jun 20, 2025	Jun 25, 2025	SEC EDGAR
Current report	8-K	May 21, 2025	May 23, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 7, 2025	May 7, 2025	SEC EDGAR
Current report	8-K	Apr 23, 2025	Apr 23, 2025	SEC EDGAR
Proxy statement	DEF 14A	May 21, 2025	Apr 4, 2025	SEC EDGAR
Current report	8-K	Mar 28, 2025	Apr 3, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 3, 2025	Mar 3, 2025	SEC EDGAR
Current report	8-K	Feb 24, 2025	Feb 25, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Current report	8-K	Nov 15, 2024	Nov 15, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Arbutus Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Nov 4, 2010
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABUS.

Compare: ABUS vs ASMB · ABUS vs ANAB · ABUS vs ENTA · ABUS vs RCUS · ABUS vs KPTI

Revenue growth1142.6% · median 49.9%

Operating margin81.1% · median -56.2%

Net margin121.2% · median -96.9%

Company	Revenue	Growth
ANAB	$237.61M	+92.9%
ABUS	$181.49M	+1142.6%
KPTI	$146.62M	+6.8%
RCUS	$100.00M	-58.3%
ASMB	$74.85M	+125.1%
ENTA	$65.26M	–

Company

Next earnings (est.): Mar 22, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 19
Held by institutions: 71.1%
Auditor: Ernst & Young LLP
SEC CIK: 1447028

Advertisement
300 × 250

See a number that looks wrong?